-+ 0.00%
-+ 0.00%
-+ 0.00%

HUTCHMED says savolitinib plus AstraZeneca’s Tagrisso extends PFS in China Phase III SANOVO lung cancer trial

PUBT·08/31/2026 07:15:21
Listen to the news
HUTCHMED says savolitinib plus AstraZeneca’s Tagrisso extends PFS in China Phase III SANOVO lung cancer trial
  • HUTCHMED reported positive high-level results from the SANOVO China Phase III trial in first-line EGFR-mutated NSCLC with MET overexpression.
  • ORPATHYS with TAGRISSO extended the time patients lived without disease worsening versus TAGRISSO alone in both key study populations.
  • Overall survival trends also favored the combination; follow-up continues to confirm durability of benefit.
  • Results will be presented at a future medical meeting.
  • Safety matched the known profiles of each drug, supporting plans to engage regulators on a first-line China use case.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608302000PRIMZONEFULLFEED9818125) on August 31, 2026, and is solely responsible for the information contained therein.